Insider Selling: Abeona Therapeutics Inc. (NASDAQ:ABEO) CFO Sells 25,411 Shares of Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) CFO Joseph Walter Vazzano sold 25,411 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $148,908.46. Following the completion of the sale, the chief financial officer directly owned 479,168 shares of the company's stock, valued at $2,807,924.48. The trade was a 5.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Joseph Walter Vazzano also recently made the following trade(s):

• On Friday, June 6th, Joseph Walter Vazzano sold 17,795 shares of Abeona Therapeutics stock. The stock was sold at an average price of $6.76, for a total value of $120,294.20.

Abeona Therapeutics Stock Down 1.9%

ABEO traded down $0.11 on Friday, reaching $5.74. The company's stock had a trading volume of 774,254 shares, compared to its average volume of 701,305. The stock has a market cap of $293.66 million, a price-to-earnings ratio of -4.52 and a beta of 1.51. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.32. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.90 and a quick ratio of 4.90. The business's 50 day moving average is $6.01 and its 200 day moving average is $5.57.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.11. As a group, research analysts forecast that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ABEO. Wellington Management Group LLP acquired a new stake in Abeona Therapeutics during the fourth quarter valued at approximately $520,000. Trexquant Investment LP acquired a new stake in Abeona Therapeutics during the fourth quarter valued at approximately $382,000. Adage Capital Partners GP L.L.C. raised its stake in Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after buying an additional 652,366 shares in the last quarter. Oxford Asset Management LLP acquired a new stake in Abeona Therapeutics during the fourth quarter valued at approximately $118,000. Finally, Northern Trust Corp raised its stake in Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock valued at $1,030,000 after buying an additional 11,478 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Oppenheimer assumed coverage on Abeona Therapeutics in a research report on Monday, June 2nd. They issued an "outperform" rating and a $19.00 target price for the company. Stifel Nicolaus reduced their price target on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a report on Friday, May 16th. Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. HC Wainwright increased their price target on Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. Finally, Alliance Global Partners reissued a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Abeona Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $19.25.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.